185 results on '"Colafigli M"'
Search Results
2. Efficacy and durability of two‐ vs . three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE cohort
3. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010
4. Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis
5. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group
6. Comparison of cognitive performance in HIV or HCV mono-infected and HIV–HCV co-infected patients
7. Anal human papillomavirus in HIV-uninfected men who have sex with men: incidence and clearance rates, duration of infection, and risk factors
8. Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study
9. Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients
10. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients
11. HIV MDR is still a relevant issue despite its dramatic drop over the years
12. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study
13. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection
14. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors
15. Long-term follow-up of nevirapine-treated patients in a single-centre cohort
16. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen
17. Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)
18. Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART
19. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV
20. Changes of lipid profile after switching to E/C/F/TAF: data from the Italian Compassionate Use Program
21. Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI)
22. Compassionate use of tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: an Italian experience
23. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor
24. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study
25. Survival in HIV-infected patients after a cancer diagnosis in the cART Era: results of an italian multicenter study
26. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV.
27. Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016.
28. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis
29. Declining prevalence of HIV-1 drug resistance in treatment-experienced patients: a clinical cohort study
30. Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort
31. La riduzione della prevalenza di farmacoresistenza nei pazienti con esperienze terapeutiche: varie stime secondo le diverse metodologie impiegate in uno studio clinico di coorte
32. Impact of HIV-1 genotypic resistance testing and adherence to treatment guidelines in drug naive patients
33. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor.
34. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010
35. Performance of genotypic tropism testing on proviral DNAin clinical practice: results from the DIVA Study Group
36. Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART
37. Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder(INR) HIV-1-infected patients treated with HAART
38. Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group
39. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)
40. Single-tablet regimen is associated with reduced efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients
41. Cardiovascular risk factors and carotid intima‐media thickness are associated with lower cognitive performance in HIV‐infected patients
42. P.04.13 THE KEY ROLE OF IMMUNE SYSTEM, AGE AND SEX IN THE RESPONSE TO HEPATITIS C ANTIVIRAL TREATMENT
43. Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: A cohort study
44. Genotypic Resistance Profile and Clinical Progression of Treatment-Experienced HIV Type 1-Infected Patients with Virological Failure
45. Atazanavir (ATV) plasma concentrations at different times after drug uptake: associations with virologic response and hyperbilirubinemia
46. Interpretation systems for genotypic drug resistance of HIV-1.
47. Long term follow-up of Nevirapine-treated patients in a single centre cohort
48. Prevalence of transmitted HIV-1 drug-resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors
49. Impact of transmitted drug resistance in naïve-patients starting 2 NRTI plus a boosted protease-inhibitor (PI) or integrase-inhibitor (INSTI)
50. Erratum: Declining prevalence of HIV-1 drug resistance in treatment-failing patients: A clinical cohort study (Antiviral Therapy (2007) 12, (835-839))
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.